[{"id":"c121533e-47d9-4ac4-9593-e7db6d83a51b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06970132","created_at":"2025-09-07T01:34:43.364Z","updated_at":"2025-09-07T01:34:43.364Z","phase":"Phase 1/2","brief_title":"Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation","source_id_and_acronym":"NCT06970132","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e conteltinib (SY-707) • SY-5933"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-05-14"},{"id":"7114fae7-0419-4c0e-a010-ae5f4d1c710b","acronym":"AEWS1221","url":"https://clinicaltrials.gov/study/NCT02306161","created_at":"2023-11-28T02:14:27.984Z","updated_at":"2025-02-25T16:36:29.981Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT02306161 - AEWS1221","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 09/19/2025","study_completion_date":" 09/19/2025","last_update_posted":"2025-02-06"},{"id":"a6d31f53-b654-4da8-90c1-1275e4f0fcec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04485949","created_at":"2024-03-05T19:33:23.646Z","updated_at":"2024-07-02T16:34:59.826Z","phase":"Phase 2","brief_title":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","source_id_and_acronym":"NCT04485949","lead_sponsor":"Imvax","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • IGV-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-05-31"},{"id":"310e631e-b071-40b1-a519-01d9a5329dbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129151","created_at":"2021-01-18T20:10:20.167Z","updated_at":"2024-07-02T16:35:55.610Z","phase":"Phase 2","brief_title":"Palbociclib + Ganitumab In Ewing Sarcoma","source_id_and_acronym":"NCT04129151","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDK4 • EWSR1 • IGF1 • FLI1 • FUS","pipe":"","alterations":" ","tags":["CDK4 • EWSR1 • IGF1 • FLI1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ganitumab (AMG 479)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-02-14"},{"id":"336b2a89-c159-43c3-97a3-1a3d4e0383e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01154335","created_at":"2021-01-18T04:35:39.864Z","updated_at":"2025-02-25T15:32:14.079Z","phase":"Phase 1","brief_title":"Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01154335","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2022-05-03"},{"id":"d399bf26-299c-4709-84ee-4bdf85e1b0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00617708","created_at":"2021-01-18T02:17:45.723Z","updated_at":"2024-07-02T16:36:17.448Z","phase":"Phase 2","brief_title":"S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00617708","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 02/25/2014","study_completion_date":" 02/25/2014","last_update_posted":"2022-02-08"},{"id":"c7430dc9-01ea-42e0-b7c3-86cf71195b7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446159","created_at":"2021-01-18T05:59:58.146Z","updated_at":"2024-07-02T16:36:44.570Z","phase":"Phase 1b/2","brief_title":"Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer","source_id_and_acronym":"NCT01446159","lead_sponsor":"MedImmune LLC","biomarkers":" HER-2 • IGF2","pipe":"","alterations":" ","tags":["HER-2 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • dusigitumab (MEDI-573)"],"overall_status":"Completed","enrollment":" Enrollment 188","initiation":"Initiation: 06/13/2011","start_date":" 06/13/2011","primary_txt":" Primary completion: 06/28/2019","primary_completion_date":" 06/28/2019","study_txt":" Completion: 06/28/2019","study_completion_date":" 06/28/2019","last_update_posted":"2020-06-02"},{"id":"3cf0256f-0bef-4a24-b288-c72267995e10","acronym":"","url":"https://clinicaltrials.gov/study/NCT00684983","created_at":"2021-01-18T02:33:37.670Z","updated_at":"2024-07-02T16:36:47.849Z","phase":"Phase 2","brief_title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","source_id_and_acronym":"NCT00684983","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/30/2008","start_date":" 07/30/2008","primary_txt":" Primary completion: 01/07/2014","primary_completion_date":" 01/07/2014","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2020-03-24"},{"id":"594ccd90-691a-4aa9-a0de-882c8c5b0c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT00957853","created_at":"2021-01-18T03:43:39.679Z","updated_at":"2024-07-02T16:36:47.961Z","phase":"Phase 2","brief_title":"Preoperative Treatment With Cetuximab and/or IMC-A12","source_id_and_acronym":"NCT00957853","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/17/2011","start_date":" 10/17/2011","primary_txt":" Primary completion: 08/15/2018","primary_completion_date":" 08/15/2018","study_txt":" Completion: 08/15/2018","study_completion_date":" 08/15/2018","last_update_posted":"2020-03-19"},{"id":"00f37282-88de-4fc3-b91a-1df12b6d5136","acronym":"","url":"https://clinicaltrials.gov/study/NCT00889382","created_at":"2021-01-18T03:24:17.372Z","updated_at":"2024-07-02T16:36:53.424Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)","source_id_and_acronym":"NCT00889382","lead_sponsor":"Astellas Pharma Inc","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 152","initiation":"Initiation: 08/05/2009","start_date":" 08/05/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/25/2014","study_completion_date":" 08/25/2014","last_update_posted":"2019-11-19"},{"id":"d1f2bba3-a066-4ab2-ade4-ee5dabc41dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00781911","created_at":"2021-01-18T02:57:16.581Z","updated_at":"2024-07-02T16:36:55.434Z","phase":"Phase 2","brief_title":"A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer","source_id_and_acronym":"NCT00781911","lead_sponsor":"Eli Lilly and Company","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cixutumumab (IMC A12) • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2019-09-20"},{"id":"ebcb72d9-4f33-4bf8-b8a2-f84673232821","acronym":"","url":"https://clinicaltrials.gov/study/NCT01232452","created_at":"2021-01-18T04:57:21.834Z","updated_at":"2024-07-02T16:36:55.407Z","phase":"Phase 2","brief_title":"A Study in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01232452","lead_sponsor":"Eli Lilly and Company","biomarkers":" IGF1 • IGFBP3","pipe":"","alterations":" ","tags":["IGF1 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2019-09-20"},{"id":"8db1babf-60a4-4a8c-891a-de73990bbe97","acronym":"BATTLE-FL","url":"https://clinicaltrials.gov/study/NCT01263782","created_at":"2021-01-18T05:06:06.604Z","updated_at":"2024-07-02T16:36:59.589Z","phase":"Phase 2","brief_title":"BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer","source_id_and_acronym":"NCT01263782 - BATTLE-FL","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • pemetrexed • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 05/17/2011","start_date":" 05/17/2011","primary_txt":" Primary completion: 08/15/2017","primary_completion_date":" 08/15/2017","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2019-05-15"},{"id":"357dc3dd-3511-4e3e-92dc-2dae662ea8ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816361","created_at":"2021-01-18T03:06:08.124Z","updated_at":"2024-07-02T16:37:02.295Z","phase":"Phase 1","brief_title":"A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT00816361","lead_sponsor":"MedImmune LLC","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dusigitumab (MEDI-573)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/09/2009","start_date":" 03/09/2009","primary_txt":" Primary completion: 09/11/2012","primary_completion_date":" 09/11/2012","study_txt":" Completion: 09/11/2012","study_completion_date":" 09/11/2012","last_update_posted":"2019-03-04"},{"id":"4df1a9e2-4955-42a1-a861-a13e5b341fa9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01221077","created_at":"2021-01-18T04:54:20.608Z","updated_at":"2024-07-02T16:37:03.502Z","phase":"Phase 2","brief_title":"Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene","source_id_and_acronym":"NCT01221077","lead_sponsor":"Astellas Pharma Inc","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 04/08/2011","start_date":" 04/08/2011","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 09/01/2014","study_completion_date":" 09/01/2014","last_update_posted":"2019-01-24"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"},{"id":"0d8d95d1-e811-40d1-bfc3-cea16cccfecf","acronym":"CARRIE","url":"https://clinicaltrials.gov/study/NCT02399137","created_at":"2021-01-18T11:26:45.591Z","updated_at":"2024-07-02T16:37:06.821Z","phase":"Phase 2","brief_title":"A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02399137 - CARRIE","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2018-09-18"},{"id":"4fe00c35-b65b-4356-9132-931ccb374a01","acronym":"","url":"https://clinicaltrials.gov/study/NCT01186861","created_at":"2021-01-18T04:44:45.330Z","updated_at":"2024-07-02T16:37:07.249Z","phase":"Phase 2","brief_title":"Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","source_id_and_acronym":"NCT01186861","lead_sponsor":"Astellas Pharma Inc","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • linsitinib (ASP7487)"],"overall_status":"Completed","enrollment":" Enrollment 205","initiation":"Initiation: 03/04/2011","start_date":" 03/04/2011","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/11/2015","study_completion_date":" 03/11/2015","last_update_posted":"2018-09-05"},{"id":"00dab510-ce67-4a8e-8ef1-dc0dba1fc50e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00759785","created_at":"2021-01-18T02:52:13.209Z","updated_at":"2024-07-02T16:37:07.885Z","phase":"Phase 1","brief_title":"A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)","source_id_and_acronym":"NCT00759785","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/30/2008","start_date":" 09/30/2008","primary_txt":" Primary completion: 02/17/2010","primary_completion_date":" 02/17/2010","study_txt":" Completion: 02/17/2010","study_completion_date":" 02/17/2010","last_update_posted":"2018-08-15"},{"id":"b0fef793-7b81-42b4-ba49-db123c09fe43","acronym":"","url":"https://clinicaltrials.gov/study/NCT00614393","created_at":"2021-01-18T02:16:58.601Z","updated_at":"2024-07-02T16:37:08.137Z","phase":"Phase 2","brief_title":"Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)","source_id_and_acronym":"NCT00614393","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 558","initiation":"Initiation: 12/24/2007","start_date":" 12/24/2007","primary_txt":" Primary completion: 06/01/2010","primary_completion_date":" 06/01/2010","study_txt":" Completion: 03/07/2012","study_completion_date":" 03/07/2012","last_update_posted":"2018-08-08"},{"id":"95b9c453-8e97-4f5a-abdf-aa632ad35d9c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00728949","created_at":"2021-01-18T02:44:40.539Z","updated_at":"2024-07-02T16:37:10.242Z","phase":"Phase 2","brief_title":"A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer","source_id_and_acronym":"NCT00728949","lead_sponsor":"Eli Lilly and Company","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 02/01/2015","study_completion_date":" 02/01/2015","last_update_posted":"2018-06-06"},{"id":"f71419e3-ec56-43d9-8477-d9001d63eb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT00503685","created_at":"2021-01-18T01:48:22.198Z","updated_at":"2024-07-02T16:37:10.264Z","phase":"Phase 2","brief_title":"Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy","source_id_and_acronym":"NCT00503685","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1","tags":["KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 03/01/2009","study_completion_date":" 03/01/2009","last_update_posted":"2018-06-06"},{"id":"37e90df5-af6e-4285-9888-443417e0a288","acronym":"","url":"https://clinicaltrials.gov/study/NCT01182883","created_at":"2021-01-18T04:43:35.712Z","updated_at":"2024-07-02T16:37:20.233Z","phase":"Phase 1","brief_title":"A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT01182883","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2010","start_date":" 07/28/2010","primary_txt":" Primary completion: 04/04/2012","primary_completion_date":" 04/04/2012","study_txt":" Completion: 04/04/2012","study_completion_date":" 04/04/2012","last_update_posted":"2017-07-02"},{"id":"a029591e-46da-4354-9f40-6f34e9c1d8c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01234857","created_at":"2021-01-18T04:58:05.618Z","updated_at":"2024-07-02T16:37:21.547Z","phase":"Phase 2","brief_title":"A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)","source_id_and_acronym":"NCT01234857","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 09/17/2010","start_date":" 09/17/2010","primary_txt":" Primary completion: 10/15/2013","primary_completion_date":" 10/15/2013","study_txt":" Completion: 10/15/2013","study_completion_date":" 10/15/2013","last_update_posted":"2017-05-31"}]